Dr. Kimberly Lakin specializes in the care of patients with various rheumatic conditions including systemic sclerosis (scleroderma), Raynaud’s phenomenon, mixed connective tissue disease, systemic lupus erythematosus, and others, and has a particular interest in systemic sclerosis. Dr. Lakin is also actively involved as an investigator in numerous clinical and translational studies focusing on systemic sclerosis.
Dr. Lakin received her Bachelor of Science from the University of Virginia. She attended medical school at Georgetown University where she graduated cum laude. She completed residency training in internal medicine at Northwestern University and her rheumatology fellowship training at HSS. Additionally, she received her master's degree in clinical and translational research from Weill Cornell Medicine.
Currently, she conducts clinical and translational research in systemic sclerosis, with a focus on testing novel therapeutics, improving trial outcome measurement tools, and determining predictive patient factors that may assist with personalized disease management. She has received funding and recognition for her research including the Rheumatology Research Foundation Resident Research Preceptorship Award, the Scleroderma Clinical Trials Consortium Young Investigator Award, and the Scleroderma Foundation New Investigator Grant.
Scleroderma, Vasculitis & Myositis Center of Excellence
Scleroderma (systemic sclerosis and localized scleroderma)
Mixed connective tissue disease
Systemic lupus erythematosus
Intra-articular aspirations and injections
If your insurance is not listed, please call our office if you have questions regarding your insurance coverage. If you have out-of-network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.
Assistant Attending Physician, Hospital for Special Surgery
Assistant Professor of Medicine, Weill Cornell Medical College
Member, American College of Rheumatology
Member, American Medical Association
American Board of Internal Medicine, Internal Medicine, 2017
American Board of Internal Medicine, Rheumatology, 2019
Charles L. Christian Award for Excellence in Musculoskeletal Research, 2020
Scleroderma Clinical Trials Consortium, Travel Award, 2020
Scleroderma Clinical Trials Consortium, Young Investigator Award, 2019
Alpha Omega Alpha Honor Society, 2013
Scleroderma Foundation New Investigator Grant, 2020
Georgetown University School of Medicine, 2014
Internal Medicine, McGaw Medical Center of Northwestern University, 2015
Internal Medicine, McGaw Medical Center of Northwestern University, 2017
Rheumatology, Hospital for Special Surgery, 2020
Showalter K., Hoffmann A., Rouleau G., Aaby D., Lee J., Richardson C., Dematte J., Agrawal R., Chang R.W., Hinchcliff M. Performance of forced vital capacity and lung diffusion cut-points for associated radiographic interstitial lung disease in systemic sclerosis. Abstract for poster presentation. American College of Rheumatology 2017 Annual Meeting, San Diego, CA, November 2017.
Showalter K., Pinheiro L., Szymonifka J., Sobol I., Steen V., Gordon J.K. Patient-level factors associated with hospital readmission among patients with systemic sclerosis associated pulmonary hypertension. Abstract for poster presentation. American College of Rheumatology 2018 Annual Meeting. Chicago, IL, October 2018.
Showalter K., Magro C., Orange D., Zhang Y., Agius P., Finik J., Spiera R., Gordon J.K. Histologic features correlate with the modified Rodnan skin score, serum inflammatory markers, and patient reported outcomes in patients with early, diffuse cutaneous systemic sclerosis. Abstract for oral presentation. 16th International Workshop on Scleroderma Research, University of Cambridge. Cambridge, U.K., July 2019.
Showalter K., Spiera R., Orange D., Magro C., Zhang Y., Finik J., Gordon J.K. Change in skin histology correlates with the Combined Response Index in Systemic Sclerosis (CRISS) in patients with early, diffuse cutaneous systemic sclerosis. Abstract for oral presentation. American College of Rheumatology 2019 Annual Meeting, Atlanta, GA, November 2019.
Showalter K., Smith M., Cheah J., Ghosh N., Gkrouzman E., Lieber S., Sattui Cortes S., Schwartz N., Schwartzman M., Berman J., Sammaritano L., Bass A. Reproductive counseling documentation practices for women receiving teratogenic medications in an academic rheumatology clinic serving a Medicaid/Medicare patient population. Abstract for poster presentation. American College of Rheumatology 2019 Annual Meeting, Atlanta, GA, November 2019.
Showalter K., Hoffmann A., Richardson C., Koloms K., Rouleau G., Aaby D., Lee J., Dematte J., Agrawal R., Wu X., Chang R.W., Hinchcliff M. Esophageal dilation and other clinical factors associated with pulmonary function decline in patients with systemic sclerosis. Abstract for poster presentation. American College of Rheumatology 2019 Annual Meeting, Atlanta, GA, November 2019.
Showalter K., Orange D., Magro, C., Agius, P., Martyanov, V., Franks, J., Sharma, R., Geiger, H., Wood, T., Zhang, Y., Spiera, R., Whitfield, M, Gordon, J. CD34 and alpha-smooth muscle actin distinguish scleroderma gene expression subsets using a machine learning approach. Abstract for poster presentation. Systemic Sclerosis World Congress Meeting, Prague, Czech Republic, (Meeting postponed from March 2020 and held virtually July 2020).
Showalter K, Gordon JK, Wu, Y, Kwakkenbos L, Carrier ME, Henry R, Wu Y, Ostbo N, Nordlund J, Bourgeault A, Ayala MC, Discepola MN, Denton C, Mouthon L, Thombs B, Spiera RF. Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. Arthritis Rheumatol, 2021: 73 (suppl 10) ACR Convergence 2021
Dr. Lakin conducts clinical and translational research in systemic sclerosis, with a focus on testing novel therapeutics, improving trial outcome measurement tools, and determining predictive patient factors that may assist with personalized disease management.
One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.
As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.
As of July 31, 2020, Dr. Showalter reported no relationships with the healthcare industry.
By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.